Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

4 terminated/withdrawn out of 10 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 2

2(22.2%)

N/A

2(22.2%)

Phase 3

1(11.1%)

9Total

Phase 1(4)

Phase 2(2)

N/A(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07572162Not Yet Recruiting

Post-market Safety Study of LUMISIGHT

Role: lead

NCT02584244Phase 1Recruiting

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

Role: lead

NCT03834272Phase 1Completed

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

Role: lead

NCT03717142Not ApplicableTerminated

Feasibility of the LUM Imaging System for Detection of Cancer to the Brain

Role: lead

NCT04440982Phase 2Terminated

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Role: lead

NCT04276909Not ApplicableWithdrawn

Feasibility Study of LUM Imaging System for Pancreatic Cancer

Role: lead

NCT03686215Phase 3Completed

Investigation of Novel Surgical Imaging for Tumor Excision

Role: lead

NCT03321929Phase 2Completed

Intraoperative Detection of Residual Cancer in Breast Cancer

Role: lead

NCT02438358Phase 1Completed

Feasibility Study of Intraoperative Imaging in Breast Cancer

Role: lead

NCT03441464Phase 1Terminated

Feasibility of the LUM Imaging System for Detection of Prostate Cancer

Role: lead

All 10 trials loaded